A new mechanism of RhoA ubiquitination and degradation: Roles of SCFFBXL19 E3 ligase and Erk2  by Wei, Jianxin et al.
Biochimica et Biophysica Acta 1833 (2013) 2757–2764
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrA new mechanism of RhoA ubiquitination and degradation:
Roles of SCFFBXL19 E3 ligase and Erk2Jianxin Wei a, Rachel K. Mialki a, Su Dong a,d, Andrew Khoo a, Rama K. Mallampalli a,b,c,
Yutong Zhao a,1, Jing Zhao a,⁎
a Department of Medicine and the Acute Lung Injury Center of Excellence, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
b Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
c Medical Specialty Service Line, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, USA
d Department of Anesthesia, First Hospital of Jilin University, Changchun, Jilin, China⁎ Corresponding author at: Department of Medicine, Un
Medicine, 3459 Fifth Avenue, NW 628MUH, Pittsburgh, PA
0843; fax: +1 412 383 7113.
E-mail address: zhaoj@upmc.edu (J. Zhao).
1 Co-senior authors of this work.
0167-4889/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbamcr.2013.07.005a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 April 2013
Received in revised form 19 June 2013
Accepted 8 July 2013
Available online 18 July 2013
Keywords:
Small GTPase protein
Protein stability
Ubiquitin-proteasome system
Phosphorylation
Cell proliferation
Stress ﬁberRhoA is a small GTPase multifunctional protein that regulates cell proliferation and cytoskeletal reorganization.
Regulation of its protein stability plays an important role in its biological functions. We have shown that a
Skp1-Cul1-F-box (SCF) FBXL19 E3 ubiquitin ligase targets Rac1, a related member of the Rho family for
ubiquitination and degradation. Here, SCFFBXL19 mediates RhoA ubiquitination and proteasomal degradation in
lung epithelial cells. Ectopically expressed FBXL19 decreased RhoAwild type, active, and inactive forms. Cellular
depletion of FBXL19 increased RhoA protein levels and extended its half-life. FBXL19 bound the small GTPase in
the cytoplasm leading to RhoA ubiquitination at Lys135. A RhoAK135R mutant protein was resistant to SCFFBXL19-
mediated ubiquitination and degradation and exhibited a longer lifespan. Protein kinase Erk2-mediated phos-
phorylation of RhoA was both sufﬁcient and required for SCFFBXL19-mediated RhoA ubiquitination and degrada-
tion. Thus, SCFFBXL19 targets RhoA for its disposal, a process regulated by Erk2. Ectopically expressed FBXL19
reduced phosphorylation of p27 and cell proliferation, a process mediated by RhoA. Further, FBXL19 cellular
expression diminished lysophosphatidic acid (LPA)-induced phosphorylation of myosin light chain (MLC) and
stress ﬁber formation. Hence, SCFFBXL19 functions as a RhoA antagonist during cell proliferation and cytoskeleton
rearrangement. These results provide the ﬁrst evidence of an F-box protein targeting RhoA thereby modulating
its cellular lifespan that impacts cell proliferation and cytoskeleton rearrangement.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Small GTPase proteins regulate numerous cellular functions includ-
ing cell cycle progression, cytoskeletal rearrangement, and regulation
of transcriptional factor activity [1,2]. Their activation is dependent on
interaction with guanine nucleotides. The small GTPases are activated
in a GTP bound state but are inactivated when bound to GDP [3]. RhoA
is a member of the RhoGTPases that control cell proliferation and cyto-
skeletal stress ﬁber formation [4–6]. Similar to other small GTPases,
RhoA activity is activated by guanine-nucleotide exchange factors
(GEFs) and is inactivated by guanine-nucleotide dissociation inhibitors
(GDIs), which regulate cycling between a GTP- and a GDP-bound state
[7]. Recent studies suggest that regulatory control of RhoA protein
stability plays a critical role in RhoA-mediated cellular signaling
and biological functions [8,9].iversity of Pittsburgh School of
, 15213, USA. Tel.: +1 412 648
ights reserved.Protein ubiquitination is amajor post-translationalmodiﬁcation that
regulates protein stability [10–14]. Ubiquitin is a small protein consisting
of 76 amino acids, which covalently attaches to proteins, thereby
directing proteins to the proteasome or lysosome for degradation.
Protein ubiquitination requires a sequential series of steps: activation
of ubiquitin by E1 ubiquitin-activating enzyme; transferring ubiquitin
from an E1 enzyme to a ubiquitin-conjugating enzyme E2; and attach-
ment of a mono- or poly-ubiquitin chain to substrates via an E3 ligase
[14]. The Skp1-Cul1-F-box protein (SCF) ligase complex is one of the
largest E3 ubiquitin ligase families [15,16]. The F-box protein in the E3
ligase complex speciﬁcally interacts with substrates. It is common for
one F-box protein to target more than one substrate. For example,
β-Trcp1 (also termed FBXW1a) targets both phosphorylated-I-κB [17]
as well as cortactin [18] for their ubiquitination and degradation. We
have demonstrated that FBXL19, a new member of the F-box protein
family, targets the IL-33 cognate receptor, ST2L, for its ubiquitination
and proteasomal degradation [19]. In addition to ST2L, we recently
found that Rac1 is another target for FBXL19. Over-expression of
FBXL19 reduced both active and inactive forms of Rac1 protein [20].
Several groups have attempted to identifywhich E3 ligase apparatus
catalyzes RhoA ubiquitination for its ultimate degradation in cells
2758 J. Wei et al. / Biochimica et Biophysica Acta 1833 (2013) 2757–2764[8,9,21]. Smurf1 appears to target activated RhoA [9], while Cullin-3/
BACURD targets only GDP-bound RhoA for its ubiquitination and degra-
dation [8]. Here, we show that SCFFBXL19 uniquely targets both the active
and inactive forms of RhoA for ubiquitination and degradation, a pro-
cess facilitated by extracellular signal-regulated kinase 2 (Erk2) that
phosphorylates the GTPase. Further, we demonstrated that ectopically
expressed FBXL19 reduces RhoA-mediated cell proliferation and stress
ﬁber formation. The data suggests that in addition to ST2L and Rac1,
RhoA is a new identiﬁed substrate for SCFFBXL19.2. Materials and methods
2.1. Cell culture and reagents
Murine lung epithelial cells (MLE12)were fromATCC (Manassas, VA,
USA). Cells were cultured with HITES medium containing 10% fetal
bovine serum(FBS) and antibiotics in a 5% CO2 incubator at 37 °C. V5 an-
tibody, mammalian expression plasmid pcDNA3.1D/His-V5-TOPO, and
Escherichia coli Top10 competent cells were from Invitrogen (Carlsbad,
CA, USA). HA tag (29 F4) and ubiquitin (P4D1) antibodies were
from Cell Signaling Technology (Danvers, MA, USA). Cycloheximide,
leupeptin, β-actin antibody, individual FBXL19 shRNAs, and scrambled
shRNA were from Sigma-Aldrich (St. Louis, MO, USA). MG-132 and
PD98059 were from Calbiochem. RhoA, Erk2, phospho-MLC, and
phospho-p27 antibodies, immunobilized protein A/G beads, and control
IgG were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). FBXL19
antibody was from Abgent (San Diego, CA, USA). All materials in the
highest grades used in the experiments are commercially available.2.2. Construction of FBXL19 and RhoA plasmids
The FBXL19 cDNA was inserted into a pcDNA3.1D/V5-His vector
(Invitrogen, CA, USA) [19]. Site directed mutagenesis was performed to
generate RhoA lysine or serine mutants according to the manufacturer's
instructions (Agilent Technologies, Santa Clara, CA, USA).2.3. Immunoblotting and immunoprecipitation
Cells were washed with cold PBS and collected in lysis buffer con-
taining 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EGTA, 5 mM
β-glycerophosphate, 1 mM MgCl2, 1% Triton X-100, 1 mM sodium
orthovanadate, 10 μg/ml protease inhibitors, 1 μg/ml aprotinin, 1 μg/ml
leupeptin, and 1 μg/ml pepstatin. Equal amounts of cell lysates (20 μg)
were subjected to SDS–PAGE, electrotransferred to membranes and
immunoblotted with indicated antibodies. For immunoprecipitation,
equal amounts of cell lysates (1 mg) were incubated with speciﬁc pri-
mary antibodies overnight at 4 °C followed by the addition of 40 μl of
protein A/G-agarose for 2 h at 4 °C. The immunoprecipitated com-
plex was washed three times with 1% Tritonx-100 in ice-cold
phosphate-buffered saline and analyzed by immunoblotting with indi-
cated antibodies.2.4. Immunostaining
Cells grownon35-mmglass-bottom culture disheswereﬁxed in 3.7%
of formaldehyde for 20 min, followed by permeabilization with 0.1% of
TritonX-100 for 2 min. Cells were incubated with a 1:200 dilution of an-
tibodies to RhoA or V5 tag, followed by a 1:200 dilution of ﬂuorescence-
conjugated secondary antibody sequentially for immunostaining. The
actin cytoskeleton was stained with ﬂuorescence-conjugated phalloidin.
Immunoﬂuorescent cell imaging was performed using a Nikon confocal
microscope.2.5. Plasmid transfection by electroporation
MLE cells were suspended in 120 μl of nucleofection buffer and
mixed well with 3 μg of plasmid DNA in an electroporation cuvette.
Electroporation was performed in the Nucleofection™ II System
(Lonza, Gaithersburg, MD, USA), and the cells were cultured in 2 ml of
complete HITES medium for 48 h. ShRNA plasmids were also delivered
into cells by using nucleofectionwith the same protocol. Cells were cul-
tured for 72 h [19].
2.6. In vitro translation of cDNA of RhoA and FBXL19
In vitro transcription and translation (TnT) was performed using an
in vitro translation system from Promega, Inc. according to the manu-
facturer's instructions [19]. Translated RhoA and FBXL19 were con-
ﬁrmed by immunoblotting.
2.7. In vitro ubiquitin conjugation assay
The ubiquitination of RhoA by FBXL19 was performed in a reaction
mixture containing synthesized substrates, 50 mM Tris (pH 7.6),
5 mM MgCl2, 0.6 mM DTT, 2 mM ATP, 1.5 ng/μl E1, 10 ng/μl Ubc5,
10 ng/μl Ubc7, 1 μg/μl ubiquitin, 1 μM ubiquitin aldehyde, and His-
puriﬁed recombinant Cullin 1, Skp1, Rbx1 (Boston Biochem, Cambridge,
MA, USA), and synthesized F-box proteins from TnT system. The mix-
tures were subjected to immunoblotting.
2.8. Cell proliferation assay
MLE12 cells were plated in a 96-wellmicroplate at a density of 5000
cells per well in serum-free (blank) medium or 2% FBS medium. After
culturing for 48 h, cell proliferation was measured by a CyQUANT NF
Cell Proliferation Assay Kit (Invitrogen). Brieﬂy, 100 μl of 1× dye bind-
ing solution was dispensed into each microplate well using a multi-
channel pipettor. The microplate was incubated at 37 °C for 30 min.
The ﬂuorescence intensity of each sample was then measured using a
ﬂuorescence microplate reader with excitation at ~485 nm and emis-
sion detection at ~530 nm.
2.9. Statistics
All results were subjected to statistical analysis using two-way anal-
ysis of variance, and, wherever appropriate, analyzed by Student–
Newman–Keuls test. Data are expressed as mean + S.D. of triplicate
samples from at least three independent experiments and values that
were p b 0.05 were considered statistically signiﬁcant.
3. Results
3.1. RhoA degradation is through the proteasome system
To investigate if lung epithelial cells contain a functional apparatus to
degrade RhoA, we ﬁrst examined the half-life of RhoA, both the wild
type, active form, and the inactive form in MLE12 cells. V5 tagged RhoA
wild type, active form (RhoAV14), or an inactive form (RhoAN19)
over-expressing MLE12 cells were treated with a protein synthesis
inhibitor (cycloheximide, CHX); the half-life of RhoA wild type,
RhoAV14, or RhoAN19 was then determined by immunoblotting. As
shown in Fig. 1A, in the presence of CHX, all the wild type, active, and
inactive forms of RhoA degraded to ~50% around 2 h. To investigate
which degradation pathway is involved in RhoA degradation, RhoAV14
or RhoAN19 over-expressing cells were incubated with proteasome
inhibitor (MG-132) or lysosome inhibitor (leupeptin) prior to CHX
treatment. CHX-mediated RhoAV14 or RhoAN19 degradation was at-
tenuated by pretreatment with MG-132, but not leupeptin (Fig. 1B).
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Fig. 1.RhoAdegrades in theproteasome system in lung epithelial cells. A.MLE12 cellswere transfectedwith V5 tagged RhoAwild type (RhoA-V5), RhoA active form (RhoAV14-V5), or RhoA
inactive form (RhoAN19-V5) plasmids for 48 h. Cellswere treatedwith cycloheximide (CHX, 20 μg/ml) for the indicated times and then cell lysateswere analyzed for over-expressed RhoA
and β-actin by immunoblotting with V5 tag and β-actin antibodies. B. RhoAV14-V5 over-expressed MLE12 cells were treated with 20 μg/ml of CHX with or without MG-132 (20 μM) or
leupeptin (100 μM) for 2 h. Cell lysates were analyzed for RhoAV14-V5 and β-actin by immunoblotting with V5 tag and β-actin antibodies. C. RhoAN19-V5 over-expressed MLE12 cells
were treated with 20 μg/ml of CHX with or withoutMG-132 (20 μM) or leupeptin (100 μM) for 2 h. Cell lysates were analyzed for RhoAN19-V5 and β-actin by immunoblotting with V5
tag and β-actin antibodies. Shown are representative blots from three independent experiments.
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degraded by the proteasome system [22,23].
3.2. SCFFBXL19 triggers RhoA degradation
We have shown that a subunit of the SCF E3 ligase family (termed
FBXL19) targets Rac1 for its ubiquitination and degradation [20]. ToFB
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Fig. 2. FBXL19 regulates RhoA stability. A.MLE12 cells were transfectedwith three distinct FBXL1
by immunoblotting. B. MLE12 cells were co-transfected with FBXL19-V5 plasmid and RhoA-V
RhoAV14-V5, RhoAN19-V5, FBXL19-V5, and β-actin by immunoblotting with V5 tag and β-acti
alone, shFBXL19, or shFBXL19 + FBXL19-V5 plasmids and then cells were treated with CHX
and β-actin by immunoblotting with V5 tag, FBXL19, and β-actin antibodies. Shown are repreinvestigate if FBXL19 also regulates RhoA stability, we ﬁrst examined
endogenous RhoA levels in FBXL19 knock down cells. MLE12 cells
were transfected with three distinct individual FBXL19 shRNA for 72 h.
As shown in Fig. 2A, FBXL19 shRNAs transfection increased RhoA levels
with signiﬁcant knock down efﬁciency. To investigate if FBXL19-
induced RhoA degradation is associated with RhoA activity, we co-
expressed V5 tagged FBXL19 (FBXL19-V5) plasmid with either RhoAβ-actin
XL19-V5
hoA-V5
XL19-V5
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9 shRNA plasmids (#1–#3) for 72 h. RhoA, FBXL19, andβ-actin expressionwere analyzed
5 or RhoAV14-V5, or RhoAN19-V5 plasmids. Cell lysates were analyzed for RhoA-V5 or
n antibodies. C. RhoAN19-V5 over-expressedMLE12 cells were co-transfected with vector
(20 μg/ml) for 0–4 h. Cell lysates were analyzed for RhoAN19-V5, FBXL19-V5, FBXL19,
sentative blots from three independent experiments.
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were degraded by FBXL19-V5 (Fig. 2B). Thus, we used the RhoAN19
plasmid as an over-expression system to study the mechanisms of
RhoA degradation in the rest of the experiments. Next, the degradation
rate of RhoAN19-V5 in FBXL19 depleted cells was compared to control
shRNA transfected cells. FBXL19 shRNA transfection attenuated
RhoAN19-V5 degradation, an effect that was partially reversed by
over-expression of FBXL19-V5 in FBXL19 shRNA transfected cells
(Fig. 2C). Further, MLE12 cells were also co-transfected with
RhoAN19-V5 and HA tagged FBXL19. Co-immunoprecipitation (co-IP)
with an antibody to the V5 tag revealed that FBXL19-HA associates
with RhoAN19-V5 (Fig. 3A). Further, RhoA was detected in the
FBXL19 immunoprecipitation complex (Fig. 3B). The association be-
tween over-expressed FBXL19 and endogenous RhoA was also con-
ﬁrmed by immunostaining (Fig. 3C). RhoA and GFP tagged FBXL19
co-localize in the cytoplasm; however over-expressed FBXL19 was
also detected in the nuclei (Fig. 3C). These results indicate that SCFFBXL19
targets RhoA for degradation.
3.3. RhoA lysine135 is the ubiquitin acceptor site for FBXL19
Ubiquitin covalently attaches to lysine (K) residue(s) within a target
protein [14]. To identify the putative ubiquitin acceptor sitewithin RhoA
for the SCFFBXL19 complex,we substituted several candidate K residues of
RhoA with Arg (R). Of several mutants tested, only RhoAN19K135R was
resistant to FBXL19-mediated degradation (Fig. 4A). RhoAN19K135R
displayed greater protein stability than another mutant, RhoAN19K140R,
in response to CHX treatment (Fig. 4B). In vitro ubiquitination assays
showed that SCFFBXL19-induced polyubiquitination was reduced using
RhoAN19K135R as a substrate versus RhoAN19 (Fig. 4C). The results
suggest that FBXL19 mediates site-speciﬁc RhoA polyubiquitination.
3.4. Erk2 regulates RhoA phosphorylation and degradation
Substrate phosphorylation is often an essential step for F-box pro-
teins to recognize their substrates during proteolysis [24,25]. We have
shown that Erk2 is a key kinase in the regulation of cortactin phosphor-
ylation and subsequent degradation by SCFβ-Trcp in MLE12 cells [18]. To
investigate if Erk2 is also involved with FBXL19-mediated RhoA degra-
dation, we ﬁrst examined the effect of Erk2 on RhoA phosphorylation.
Immunoprecipitation with a RhoA antibody followed by immuno-
blotting with a speciﬁc antibody to phospho-serine shows that over-IP: HA tag
IB: V5 tag
RhoAN19-V5
FBXL19-HA
Input  lysates
A B
RhoAN19-V5
IgG HC
IB: Rh
Rh
β-ac
Fig. 3. FBXL19 interacts with RhoA. A. MLE12 cells were co-transfected with RhoAN19-V5 an
followed by V5 tag immunoblotting. Input lysates were analyzed by immunoblotting with
experiments. B. MLE12 cell lysates were subjected to immunoprecipitation with FBXL19 antib
with RhoAandβ-actin antibodies. Shownare representative blots from three independent experim
(2 μg) for 48 h followed byMG-132 (20 μM, 18 h) treatment. Localization of FBXL19-GFP (gree
show co-localization of FBXL19 and RhoA. Shown are representative images from three indepexpressed V5 tagged Erk2 increased RhoA serine phosphorylation
(Fig. 5A), while depletion of Erk2 by transfected cells with Erk2 shRNA
reduced the phosphorylation of RhoA (Fig. 5B). To investigate if Erk2-
mediated phosphorylation of RhoA is associated with RhoA degrada-
tion, RhoAN19-V5 over-expressed cells were pretreated with an inhib-
itor of the Erk pathway (PD98059) prior to CHX treatment. As shown
in Fig. 6A, PD98059 attenuated CHX-mediated RhoAN19-V5 degrada-
tion. Over-expression of Erk2 reduced protein levels of either over-
expressed RhoAN19-V5 or endogenous RhoA (Fig. 6B and 6C). Fur-
ther, PD98059 attenuated FBXL19-mediated RhoA degradation
(Fig. 6D), as well as FBXL19-mediated polyubiquitination of RhoA
(Fig. 6E), suggesting that Erk2 promotes SCFFBXL19-mediated RhoA
degradation.3.5. FBXL19 regulates cell proliferation and stress ﬁber formation
RhoA plays a critical role in regulating cell proliferation and cytoskel-
eton rearrangement [26,27]. Our ﬁndings show that FBXL19 plays a di-
rect role in the polyubiquitination and degradation of RhoA suggesting
that FBXL19may inhibit RhoA-mediated cell proliferation and cytoskel-
eton rearrangement. First, we found that down-regulation of FBXL19
by FBXL19 shRNA transfection increased cell proliferation (Fig. 7A),
suggesting that FBXL19 plays a role in the regulation of cell proliferation.
Phosphorylation of p27Kip1 at serine10 is known to promote cell cycle
progression [28,29]; FBS induced this effect was attenuated in FBXL19
over-expressed cells (Fig. 7B). As expected, over-expression of RhoA
increased cell growth; the effect was lessened in the FBXL19 over-
expressed cells (Fig. 7C). Further, the inhibitory effect of RhoA down-
regulation on cell proliferation was restored by over-expression of
RhoA wild type or RhoAK135R mutant (Fig. 7D). To investigate if
SCFFBXL19-mediated RhoA degradation regulates stress ﬁber formation,
an empty vector or FBXL19-V5 plasmid transfected MLE12 cells were
treated with LPA; phosphorylation of myosin light chain (MLC) was
then examined by immunoblotting. LPA induced the phosphorylation
of MLC in empty vector transfected cells, but not in FBXL19-V5 over-
expressed cells (Fig. 8A). Immunostaining shows that LPA treatment
induced stress ﬁber formation and the effect was attenuated by over-
expression of FBXL19 (Fig. 8B). LPA and FBS treatment had no effect of
RhoA expression (data not shown). These results suggest that SCFFBXL19
targets RhoA degradation and functions as an antagonist of RhoA in the
regulation of the cell proliferation and cytoskeletal rearrangement.RhoA FBXL19-GFP
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Fig. 4. Lysine 135 within RhoA is the ubiquitin acceptor site for FBXL19. A. MLE12 cells were co-transfected with FBXL19-V5 and RhoAN19-V5 or lysine mutant plasmids. Cell lysates were
analyzed for RhoAN19-V5, mutants, FBXL19-V5, and β-actin by immunoblotting with antibodies to V5 tag and β-actin. B. MLE12 cells were transfected with RhoAN19K135R-V5 or
RhoAN19K140R-V5 plasmid and then cells were treated with CHX for 0, 2, and 4 h. Cell lysates were analyzed for V5 tagged RhoAN19 mutants and β-actin by immunoblotting with V5
tag and β-actin antibodies. C. FBXL19-HA, RhoAN19-V5, and RhoAN19K135R–V5 were synthesized by a TnT system, and in vitro ubiquitinations were measured by incubation with E1,
E2, ubiquitin, Cullin1, Skp1, and ATP, followed by V5 tag immunoblotting. Input lysateswere analyzed for RhoAN19-V5, mutant, and FBXL19-HA by immunoblotting. Shown are represen-
tative blots from three independent experiments.
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Post-translational modiﬁcations, including ubiquitination and phos-
phorylation, regulate the function of key signalingbiomolecules bymod-
ulating their activity, localization, and protein stability. Ubiquitination of
small GTPases controls their behavior in cells, includingmigratory ability
and cell cycle progression [20,29,30]. Here, RhoA lifespan is regulated by
the SCFFBXL19 E3 ligase complex by mediating RhoA ubiquitination.
While the ability of FBXL19 on protein ubiquitination is mediated by
protein kinases, such as glycogen synthase kinase 3β (GSK3β) and
AKT, RhoA ubiquitination and degradation by the F-box protein was fa-
cilitated by an Erk2-mediated phosphorylation dependent mechanism.
FBXL19 targets RhoA for ubiquitination and degradation, thus regulating
cell growth and stress ﬁber formation suggesting that this F-box proteinIP: RhoA
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presented here provide evidence that this SCF subunit modulates pro-
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tumorogenesis.
Ubiquitination is a necessary step for protein degradation in the
proteasome system, which is catalyzed by a series critical reac-
tions [14,31]. F-box proteins, themajor component of the SCF E3 ligase
machinery, directly target substrates for their ubiquitination, thereby
playing a key role in fundamental processes such as cell replication
[32,33], transcriptional activities [17,34,35], and cell motility [20,36].
We have shown that FBXL19 targets the IL-33 receptor ST2L and Rac1B
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Fig. 7. FBXL19 regulates cell proliferation. A. MLE12 cells were transfected with shCont and shFBXL19 plasmid for 72 h. Cell proliferation was measured. *p b 0.01, compared to shCont.
B. MLE12 cells were transfected with FBXL19-V5 plasmid and then cells were treated with 2% of FBS for 30 min. Cell lysates were analyzed for FBXL19-V5, phospho-p27, and β-actin by
immunoblotting with V5 tag, p-p27, and β-actin antibodies. C. MLE12 cells were co-transfected with RhoA-V5 and FBXL19-HA. Cell numbers were accounted for 0–3 days. D. MLE12
cells were transfected with shCont, shRhoA, RhoA-V5, or RhoAK135R plasmids as indicted. Cells were treated with or without 2% of FBS for 48 h and cell proliferation was measured.
Cell proliferation was normalized to the cells without FBS (veh). *p b 0.01, compared to untransfected cells; **p b 0.05, compared to shRhoA transfected cells.
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Fig. 8. FBXL19 regulates stress ﬁber formation. A. MLE12 cells were transfectedwith FBXL19-V5 plasmid and then cells were treated with LPA (5 μM) for 5 min. Cell lysates were analyzed
for phospho-MLC, FBXL19-V5, and β-actin by immunoblotting with p-MLC, V5 tag, and β-actin antibodies. B. MLE12 cells were transfected with empty vector (a and b) or FBXL19-V5
plasmid (c-h) and then cells were treated with LPA (5 μM, 10 min) (b, f–h). Cells were ﬁxed and actin ﬁlaments were stained with phalloidin (red), FBXL19-V5 was stained with a V5
tag antibody (green), and nuclei were stained with DAPI (blue). Shown are representative images from three independent experiments. Scale bar represents 2 μm.
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tem [19]. Here we uncover that RhoA is a new substrate for FBXL19.
While the other two known E3 ligases, Smurf1 and Cullin-3/BACURD,
have been known to target only active or inactive RhoA for degradation
[8,9], over-expression of FBXL19 reduced both active and inactive RhoA
for disposal. This ﬁnding is similar to what we have recently demon-
strated that SCFFBXL19 induces Rac1 ubiquitination and degradation
in a guanine nucleotide binding independent mechanism [20]. Hence,
this study reveals a new substrate for SCFFBXL19. It is common for
F-box proteins to target multiple substrates. For example, SCFFBXW7 in-
duces polyubiquitination and degradation of Notch [35], cyclin E [37],
c-Myc [38,39] and c-Jun [35]. Lysines6,7 within RhoA have been identi-
ﬁed as ubiquitin acceptor sites by Smurf1 [22], while ubiquitin acceptor
site(s) by Cullin-3/BACURD have not been demonstrated. Here, we
identiﬁed that lysine135 is the ubiquitin acceptor site by SCFFBXL19,
since the corresponding RhoAK135R mutant has less ubiquitination,
and it is resistant to SCFFBXL19-mediated degradation. Unlike lysines 6
and 7 that are in close proximity to ﬁrst guanine nucleotide binding
site (G1), lysine135 is distant from theGTP/GDP binding sites and resides
in the linker region within α-helices 3 and 4, therefore allowing
ubiquitin linking to RhoA in both GTP- and GDP-bound states by
SCFFBXL19. Cullin-3 is a member of the SCF E3 ligase complex. Chen
et al. demonstrated that BACURD regulates Cullin-3-mediated RhoA
ubiquitination [8]. The involvement of FBXL19 in Cullin-3-mediated
RhoA ubiquitination and FBXL19 docking site within RhoA will be de-
termined in the future.
Phosphorylation of substrates is often an essential step, functioning as
a recognition signal for F-box protein interaction with substrates [24,25].
SCFβ-Trcp-mediated ubiquitination of I-κB is dependent on I-κB phosphor-
ylation by IKKs [40]. We have shown that GSK3β [19] and AKT [20] facil-
itate FBXL19-mediated ubiquitination and degradation of substrates,
such as ST2L and Rac1. Phosphorylation of RhoA by PKA at serine188 has
been known to protect RhoA from Smurf1-mediated ubiquitination and
degradation in vascular smoothmuscle cells [9]. The role of phosphoryla-
tion of RhoA in promoting its degradation has not been investigated. Erk2
is a serine/threonine kinase that regulates a variety of cellular responses
including cellular growth, differentiation, gene expression, and apoptosis
by phosphorylating numerous substrates. Several studies have demon-
strated that Erk2 promotes protein ubiquitination and degradation ofvarious targets, such as dual-speciﬁcity phosphatase 1 [41], GATA3 [42],
and cortactin [18]; however, the role of Erk2 in the regulation of RhoA
stability and activity has not been well studied. Hamadmad et al.
reported that inhibition of Erk attenuated erythropoietin-induced
RhoA activation [43]. Here, RhoA phosphorylation by Erk2 promotes
FBXL19-mediated RhoA degradation, since inhibition of the Erk path-
way attenuates RhoA ubiquitination, while over-expression of Erk2
reduces RhoA stability. Future studies will need to further clarify the
phosphodegron-likemolecular signature within RhoA that is important
in recruiting SCFFBXL19 in the context of Erk phosphorylation.
The current study unveils a newmolecularmechanism of RhoA deg-
radation. RhoA plays a critical role in regulation of cell growth and cyto-
skeleton rearrangement. Thus, it is likely that SCFFBXL19 functions as an
antagonist of RhoA and exerts divergent actions on several fundamental
processes that regulate cell growth and cell motility. Future studies will
also examine the role of FBXL19 in RhoA-mediated immune responses
and will focus on high throughput small molecule screening of novel
FBXL19 peptide mimics to manipulate cell motility.Conﬂict of interest statement
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